BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 31276749)

  • 1. Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-β in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice.
    Gali CC; Fanaee-Danesh E; Zandl-Lang M; Albrecher NM; Tam-Amersdorfer C; Stracke A; Sachdev V; Reichmann F; Sun Y; Avdili A; Reiter M; Kratky D; Holzer P; Lass A; Kandimalla KK; Panzenboeck U
    Mol Cell Neurosci; 2019 Sep; 99():103390. PubMed ID: 31276749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
    Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory effects of simvastatin and apoJ on APP processing and amyloid-β clearance in blood-brain barrier endothelial cells.
    Zandl-Lang M; Fanaee-Danesh E; Sun Y; Albrecher NM; Gali CC; Čančar I; Kober A; Tam-Amersdorfer C; Stracke A; Storck SM; Saeed A; Stefulj J; Pietrzik CU; Wilson MR; Björkhem I; Panzenboeck U
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):40-60. PubMed ID: 28941799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood-Brain Barrier.
    Zhou AL; Swaminathan SK; Salian VS; Wang L; Curran GL; Min HK; Lowe VJ; Kandimalla KK
    Mol Pharm; 2024 May; 21(5):2176-2186. PubMed ID: 38625027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
    Deane R; Sagare A; Zlokovic BV
    Curr Pharm Des; 2008; 14(16):1601-5. PubMed ID: 18673201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
    Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.
    Qosa H; Abuasal BS; Romero IA; Weksler B; Couraud PO; Keller JN; Kaddoumi A
    Neuropharmacology; 2014 Apr; 79():668-78. PubMed ID: 24467845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia.
    Yan FL; Zheng Y; Zhao FD
    Acta Neuropathol; 2008 Nov; 116(5):529-35. PubMed ID: 18830615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis.
    Zhu D; Su Y; Fu B; Xu H
    Mol Neurobiol; 2018 Sep; 55(9):7118-7131. PubMed ID: 29383689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
    Shackleton B; Crawford F; Bachmeier C
    Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of High Cholesterol Regulation of LRP1 and RAGE on Aβ Transport Across the Blood-Brain Barrier in Alzheimer's Disease.
    Zhou R; Chen LL; Yang H; Li L; Liu J; Chen L; Hong WJ; Wang CG; Ma JJ; Huang J; Zhou XF; Liu D; Zhou HD
    Curr Alzheimer Res; 2021; 18(5):428-442. PubMed ID: 34488598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier.
    Kisler K; Sagare AP; Lazic D; Bazzi S; Lawson E; Hsu CJ; Wang Y; Ramanathan A; Nelson AR; Zhao Z; Zlokovic BV
    Mol Neurodegener; 2023 Jan; 18(1):7. PubMed ID: 36707892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of mNAT1/hNAT2 Contributes to Cerebral Endothelial Necroptosis and Aβ Accumulation in Alzheimer's Disease.
    Zou C; Mifflin L; Hu Z; Zhang T; Shan B; Wang H; Xing X; Zhu H; Adiconis X; Levin JZ; Li F; Liu CF; Liu JS; Yuan J
    Cell Rep; 2020 Dec; 33(10):108447. PubMed ID: 33296651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier.
    Erickson MA; Hartvigson PE; Morofuji Y; Owen JB; Butterfield DA; Banks WA
    J Neuroinflammation; 2012 Jun; 9():150. PubMed ID: 22747709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
    Deane R; Bell RD; Sagare A; Zlokovic BV
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospholipid transfer protein is expressed in cerebrovascular endothelial cells and involved in high density lipoprotein biogenesis and remodeling at the blood-brain barrier.
    Chirackal Manavalan AP; Kober A; Metso J; Lang I; Becker T; Hasslitzer K; Zandl M; Fanaee-Danesh E; Pippal JB; Sachdev V; Kratky D; Stefulj J; Jauhiainen M; Panzenboeck U
    J Biol Chem; 2014 Feb; 289(8):4683-98. PubMed ID: 24369175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
    Ma Q; Zhao Z; Sagare AP; Wu Y; Wang M; Owens NC; Verghese PB; Herz J; Holtzman DM; Zlokovic BV
    Mol Neurodegener; 2018 Oct; 13(1):57. PubMed ID: 30340601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition.
    Jaeger LB; Dohgu S; Hwang MC; Farr SA; Murphy MP; Fleegal-DeMotta MA; Lynch JL; Robinson SM; Niehoff ML; Johnson SN; Kumar VB; Banks WA
    J Alzheimers Dis; 2009; 17(3):553-70. PubMed ID: 19433890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astaxanthin enhances autophagy, amyloid beta clearance and exerts anti-inflammatory effects in in vitro models of Alzheimer's disease-related blood brain barrier dysfunction and inflammation.
    Babalola JA; Lang M; George M; Stracke A; Tam-Amersdorfer C; Itxaso I; Lucija D; Tadic J; Schilcher I; Loeffler T; Flunkert S; Prokesch M; Leitinger G; Lass A; Hutter-Paier B; Panzenboeck U; Hoefler G
    Brain Res; 2023 Nov; 1819():148518. PubMed ID: 37579986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.
    Deane R; Wu Z; Sagare A; Davis J; Du Yan S; Hamm K; Xu F; Parisi M; LaRue B; Hu HW; Spijkers P; Guo H; Song X; Lenting PJ; Van Nostrand WE; Zlokovic BV
    Neuron; 2004 Aug; 43(3):333-44. PubMed ID: 15294142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.